PHLF < B n = 18 | PHLF > B n = 6 | p | |
---|---|---|---|
Age, years Median (range) | 70 (42–77) | 72 (60–79) | 0,773 |
Sex n(%) M/F | 12 (66)/6(33) | 1 (17)/5(83) | 0,048 |
BMI kg/m2 Median (range) | 23,3 (21–27) | 22 (19–24) | 0,786 |
ASA n(%) | 0,454 | ||
I-II | 10 (56) | 38 (50) | |
III | 8 (44) | 3 (50) | |
Bilirubine md/dl Median (range) | 0,9 (0,14–3,72) | 7,5 (4,57–14) | 0,003 |
INR Median (range) | 1,2 (1,05–1,57) | 1,57 (1,20–2,5) | 0,020 |
Creatinine mg/dl Median (range) | 0,63 (0,31–1,22) | 1,12 (0,75–1,77) | 0,010 |
Histology type n (%) | 0,321 | ||
IHCC | 5 (27) | 2 (33) | |
Hepatocarcinoma | 1 (6) | 1 (16) | |
Metastases | 12 (67) | 2 (33) | |
Sclerosing Cholangitis | 0 | 1 (16) | |
Hepatectomy n (%) | 0,127 | ||
Extended RH | 11 (61) | 2 (33) | |
Extended LH | 2 (11) | 0 | |
RH | 3 (17) | 2 (33) | |
RH + metastasect | 2 (11) | 0 | |
Extended RH + metastasectomy | 2 (11) | 1 (16) | |
Extended LH + metastasectomy | 0 | 1 (16) | |
Chemotherapy n (%) | 0,422 | ||
yes | 11 (64,7) | 3 (42,8) | |
no | 6 (35,3) | 4 (57,2) | |
Blood loss, ml Median (range) | 500 (200–800) | 200 (0–500) | 0,655 |
Hospital stay, days Median (range) | 28,7 (15–90) | 9,2 (6–35) | 0,272 |
Surgical Technique n (%) | 0,560 | ||
PVE | 3 | 10 | |
ALLPS | 3 | 8 |